Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing pattern

qqkingdom 2014-12-02

展開全文

2013Jul

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.

Clin. Exp. Rheumatol.

Clin Exp Rheumatol 2013 Jul-Aug;31(4):559-65. Epub 2013 May 27.

Esther Ramírez-Herráiz, Vicente Escudero-Vilaplana, Estefanía Ala?ón-Plaza, Nicolás Trovato-López, Ana Herranz-Alonso, Alberto Morell-Baladrón, María Sanjurjo-Sáez

View Abstract

2009Apr

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Clin Ther

Clin Ther 2009 Apr;31(4):825-35

Daniel A Ollendorf, David Klingman, Elisabeth Hazard, Saurabh Ray

View Abstract

2012Mar

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

J Med Econ

J Med Econ 2012 6;15(2):332-9. Epub 2012 Jan 6.

Chureen T Carter, Arun K Changolkar, R Scott McKenzie

View Abstract

2006Nov

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Health Technol Assess

Health Technol Assess 2006 Nov;10(42):iii-iv, xi-xiii, 1-229

Y-F Chen, P Jobanputra, P Barton, S Jowett, S Bryan, W Clark, A Fry-Smith, A Burls

View Abstract

2013Oct

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

J Manag Care Pharm

J Manag Care Pharm 2013 Oct;19(8):621-30

Vernon F Schabert, Crystal Watson, George J Joseph, Paige Iversen, Chakkarin Burudpakdee, David J Harrison

View Abstract

本站是提供個人知識管理的網(wǎng)絡(luò)存儲空間，所有內(nèi)容均由用戶發(fā)布，不代表本站觀點。請注意甄別內(nèi)容中的聯(lián)系方式、誘導(dǎo)購買等信息，謹防詐騙。如發(fā)現(xiàn)有害或侵權(quán)內(nèi)容，請點擊一鍵舉報。

轉(zhuǎn)藏 分享

QQ空間 QQ好友新浪微博微信

獻花（0） +1

來自： qqkingdom > 《TNF》

舉報/認領(lǐng)

0條評論

發(fā)表

請遵守用戶評論公約

類似文章 更多

qqkingdom

關(guān)注對話

TA的最新館藏

[轉(zhuǎn)] 科研工具|分子對接初體驗——LeDock教程
[轉(zhuǎn)] 多發(fā)性硬化(MS)新藥！CNS滲透性共價BTK抑制劑evobrutinib：治療3.5年，顯示持久臨床益處!
[轉(zhuǎn)] 免疫細胞家族成員：調(diào)節(jié)T細胞(Treg)
易錯PCR的基本原理、發(fā)展歷程及運用前景簡述,分子生物學(xué)論文
IDO抑制劑背后的故事（下）
IDO抑制劑背后的故事（上）

喜歡該文的人也喜歡更多

熱門閱讀換一換

一区二区三区日韩精品-日韩经典一区二区三区-五月激情综合丁香婷婷-欧美精品中文字幕专区

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing pattern